BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34662698)

  • 1. Classification of gadolinium-based contrast agents (GBCAs)-adverse reactions.
    Boehm IB
    Magn Reson Imaging; 2022 Jan; 85():1-2. PubMed ID: 34662698
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety issues related to intravenous contrast agent use in magnetic resonance imaging.
    Ponrartana S; Moore MM; Chan SS; Victoria T; Dillman JR; Chavhan GB
    Pediatr Radiol; 2021 May; 51(5):736-747. PubMed ID: 33871726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?
    Weinreb JC; Abu-Alfa AK
    J Magn Reson Imaging; 2009 Dec; 30(6):1236-9. PubMed ID: 19938035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gadolinium-based contrast agents in children.
    Rozenfeld MN; Podberesky DJ
    Pediatr Radiol; 2018 Aug; 48(9):1188-1196. PubMed ID: 30078039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focus on contrast-associated nephrogenic systemic fibrosis.
    Partain CL
    J Magn Reson Imaging; 2009 Dec; 30(6):1231-2. PubMed ID: 19938033
    [No Abstract]   [Full Text] [Related]  

  • 6. Nephrogenic systemic fibrosis: is gadolinium to be blamed?
    Jikki PN
    J Assoc Physicians India; 2008 Nov; 56():915-6. PubMed ID: 19263697
    [No Abstract]   [Full Text] [Related]  

  • 7. Special issue: nephrogenic systemic fibrosis.
    Leiner T; Kucharczyk W
    J Magn Reson Imaging; 2009 Dec; 30(6):1233-5. PubMed ID: 19938034
    [No Abstract]   [Full Text] [Related]  

  • 8. Gadolinium-based contrast agents: A comprehensive risk assessment.
    Fraum TJ; Ludwig DR; Bashir MR; Fowler KJ
    J Magn Reson Imaging; 2017 Aug; 46(2):338-353. PubMed ID: 28083913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Free gadolinium is a likely trigger of nephrogenic systemic fibrosis.
    Abraham JL; Edward M
    AJR Am J Roentgenol; 2009 Oct; 193(4):W354; author reply W355. PubMed ID: 19770307
    [No Abstract]   [Full Text] [Related]  

  • 10. Nephrogenic systemic fibrosis and gadolinium: a cautionary tale in the molecular imaging era.
    Wang SC
    J Med Imaging Radiat Oncol; 2008 Aug; 52(4):305-6. PubMed ID: 18811752
    [No Abstract]   [Full Text] [Related]  

  • 11. Gadolinium-associated nephrogenic systemic fibrosis in patients with renal failure: the need for an interdisciplinary helping network.
    Stratta P; Canavese C; Quaglia M; Fenoglio R
    Rheumatology (Oxford); 2010 Apr; 49(4):821-3. PubMed ID: 20032228
    [No Abstract]   [Full Text] [Related]  

  • 12. Nephrogenic systemic fibrosis.
    Weinreb JC; Kuo PH
    Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of magnetic resonance contrast media: a review with special focus on nephrogenic systemic fibrosis.
    Haneder S; Kucharczyk W; Schoenberg SO; Michaely HJ
    Top Magn Reson Imaging; 2015 Feb; 24(1):57-65. PubMed ID: 25654421
    [No Abstract]   [Full Text] [Related]  

  • 14. Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents.
    Penfield JG
    Pediatr Nephrol; 2008 Dec; 23(12):2121-9. PubMed ID: 18543004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium - 1997-2006-2016. Part 1.
    Thomsen HS
    Acta Radiol; 2016 May; 57(5):515-20. PubMed ID: 26802069
    [No Abstract]   [Full Text] [Related]  

  • 16. GBCAs and Risk for Nephrogenic Systemic Fibrosis: A Literature Review.
    Beam AS; Moore KG; Gillis SN; Ford KF; Gray T; Steinwinder AH; Graham A
    Radiol Technol; 2017 Jul; 88(6):583-589. PubMed ID: 28900045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gadolinium and nephrogenic systemic fibrosis.
    Runge VM
    AJR Am J Roentgenol; 2009 Apr; 192(4):W195-6; discussion W197. PubMed ID: 19304681
    [No Abstract]   [Full Text] [Related]  

  • 18. Nephrogenic systemic fibrosis and gadolinium-based contrast agents.
    Abu-Alfa AK
    Adv Chronic Kidney Dis; 2011 May; 18(3):188-98. PubMed ID: 21531325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium - 1997-2006-2016. Part 2.
    Thomsen HS
    Acta Radiol; 2016 Jun; 57(6):643-8. PubMed ID: 26802070
    [No Abstract]   [Full Text] [Related]  

  • 20. Gadolinium-based contrast agents and NSF: evidence from animal experience.
    Sieber MA; Steger-Hartmann T; Lengsfeld P; Pietsch H
    J Magn Reson Imaging; 2009 Dec; 30(6):1268-76. PubMed ID: 19938039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.